Medesis Pharma S.A. (ALMDP.PA)
EUR 0.34
(-2.86%)
EUR 0.34
(-2.86%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.22 Million EUR | -30.39% |
| 2022 | -3.24 Million EUR | -0.89% |
| 2021 | -3.21 Million EUR | -225.42% |
| 2020 | -987.89 Thousand EUR | -25.21% |
| 2019 | -789 Thousand EUR | 34.3% |
| 2018 | -1.2 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q4 | -1.27 Million EUR | 0.0% |
| 2023 Q2 | -839.24 Thousand EUR | 0.0% |
| 2023 Q1 | -839.24 Thousand EUR | -19.55% |
| 2023 Q3 | -1.27 Million EUR | -51.97% |
| 2023 FY | -4.22 Million EUR | -30.39% |
| 2022 Q1 | -919.79 Thousand EUR | -3.31% |
| 2022 Q4 | -701.98 Thousand EUR | 0.0% |
| 2022 Q3 | -701.98 Thousand EUR | 23.68% |
| 2022 Q2 | -919.79 Thousand EUR | 0.0% |
| 2022 FY | -3.24 Million EUR | -0.89% |
| 2021 FY | -3.21 Million EUR | -225.42% |
| 2021 Q4 | -890.33 Thousand EUR | 0.0% |
| 2021 Q3 | -890.33 Thousand EUR | -24.16% |
| 2021 Q2 | -717.07 Thousand EUR | 0.0% |
| 2021 Q1 | -717.07 Thousand EUR | -184.33% |
| 2020 FY | -987.89 Thousand EUR | -25.21% |
| 2020 Q4 | -252.19 Thousand EUR | 0.0% |
| 2020 Q3 | -252.19 Thousand EUR | -4.32% |
| 2020 Q1 | -241.74 Thousand EUR | 0.0% |
| 2020 Q2 | -241.74 Thousand EUR | 0.0% |
| 2019 FY | -789 Thousand EUR | 34.3% |
| 2018 FY | -1.2 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -23.955% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 96.68% |
| Adocia SA | -17.62 Million EUR | 76.0% |
| Aelis Farma SA | -6.46 Million EUR | 34.54% |
| Biophytis S.A. | -14.33 Million EUR | 70.492% |
| Advicenne S.A. | -6.45 Million EUR | 34.5% |
| genOway Société anonyme | 2.06 Million EUR | 304.781% |
| IntegraGen SA | -183.77 Thousand EUR | -2201.432% |
| Neovacs S.A. | -6.9 Million EUR | 38.772% |
| NFL Biosciences SA | -4.43 Million EUR | 4.539% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -443.452% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -34.81% |
| Sensorion SA | -22.31 Million EUR | 81.043% |
| Theranexus Société Anonyme | -7.64 Million EUR | 44.669% |
| TME Pharma N.V. | -5.62 Million EUR | 24.798% |
| Valbiotis SA | -7.16 Million EUR | 40.931% |
| TheraVet SA | -2.17 Million EUR | -94.443% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 79.153% |
| argenx SE | -417.15 Million EUR | 98.986% |
| BioSenic S.A. | -7.04 Million EUR | 39.924% |
| Celyad Oncology SA | -8.45 Million EUR | 49.99% |
| DBV Technologies S.A. | -85.24 Million EUR | 95.039% |
| Galapagos NV | -88.26 Million EUR | 95.208% |
| Genfit S.A. | -26.58 Million EUR | 84.088% |
| GeNeuro SA | -14.35 Million EUR | 70.542% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 73.555% |
| Innate Pharma S.A. | -12.66 Million EUR | 66.617% |
| Inventiva S.A. | -102.7 Million EUR | 95.882% |
| MaaT Pharma SA | -19.94 Million EUR | 78.793% |
| MedinCell S.A. | -20.97 Million EUR | 79.838% |
| Nanobiotix S.A. | -26.77 Million EUR | 84.207% |
| Onward Medical N.V. | -35.46 Million EUR | 88.074% |
| Oryzon Genomics S.A. | -4.54 Million EUR | 7.031% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 81.6% |
| Oxurion NV | -12.11 Million EUR | 65.076% |
| Pharming Group N.V. | -4.87 Million EUR | 13.325% |
| Poxel S.A. | -28.76 Million EUR | 85.296% |
| GenSight Biologics S.A. | -29.69 Million EUR | 85.758% |
| Transgene SA | -30.01 Million EUR | 85.908% |
| Financière de Tubize SA | -2.14 Million EUR | -97.266% |
| UCB SA | 604 Million EUR | 100.7% |
| Valneva SE | -82.08 Million EUR | 94.848% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 85.334% |